Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as XP19986 CR
XP19986 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| XP19986 CR | EXPERIMENTAL | On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of XP19986 10, 20, 40 or 60 mg. |
| Placebo for XP19986 CR | PLACEBO_COMPARATOR | On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of placebo. |
| Name | Type | Description |
|---|---|---|
| XP19986 CR | DRUG | - |
| Placebo for XP19986 CR | DRUG | - |
Inclusion Criteria: 1. History of GERD symptoms (e.g. heartburn episodes) at least 3 times per week 2. Discontinuation of drugs used to treat GERD (PPIs, H2-blockers) and/or drugs known to cause GERD symptoms (e.g. nonsteroidal anti-inflammatory drugs \[NSAIDs\]) for 7 days prior to baseline (Visit...
Top 1 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | PHAT | 2 | PHASE3 | Vonoprazan |
XP19986 is an investigational small molecule developed by Indivior Pharmaceuticals, Inc. (ticker INDV) for gastroesophageal reflux disease, or GERD. It is a controlled release formulation and has been studied in a Phase 2 clinical trial. XP19986 is not approved and remains in clinical development.
XP19986 is being developed for the treatment of gastroesophageal reflux disease, commonly known as GERD. It is an investigational therapy and has not been approved for any indication. The clinical program has focused on evaluating its efficacy and safety in patients with GERD.
XP19986 is developed by Indivior Pharmaceuticals, Inc., which trades under the ticker INDV. Indivior is the sponsor of the clinical program for XP19986 in gastroesophageal reflux disease.
XP19986 is in Phase 2 clinical development. It has completed one Phase 2 trial in patients with gastroesophageal reflux disease. The drug is investigational and has not been approved by the FDA or any regulatory authority.
XP19986 has been evaluated in one completed Phase 2 trial, NCT00838396, titled a study to evaluate the efficacy and safety of controlled release arbaclofen placarbil (XP19986) in patients with gastroesophageal reflux disease. The trial enrolled 58 patients in the United States and was randomized, double-blind, and placebo-controlled.
Yes, XP19986 CR is another name for XP19986. The CR stands for controlled release, referring to the formulation used in the clinical trial. Both names refer to the same investigational small molecule being developed by Indivior Pharmaceuticals for gastroesophageal reflux disease.